Navigation Links
PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant

DuraClean(TM) to Launch in Multiple Markets, Including Industrial

Contracted Services

SAN DIEGO, July 31 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE) today announced an agreement with DuraBan International Inc for distribution of PURE's silver dihydrogen citrate (SDC)-based disinfectant under DuraBan's DuraClean(TM) brand.


DuraBan International Inc, a Minneapolis based chemical manufacturer specializing in earth-friendly antimicrobial technologies, intends to sell DuraClean through its existing distribution channels into multiple markets, including the building, consumer products, medical, service and industrial sectors.

Robert Dahl, founder of DuraBan, commented, "DuraBan's foundation has been built on providing earth-friendly antimicrobial solutions, of which SDC powered DuraClean is a perfect example. We expect it to provide an attractive, effective and efficient solution for our customers, as DuraBan stays true to its heritage of providing safe, effective and efficient solutions to our customers in the worldwide consumer, industrial and medical marketplace."

Michael L. Krall, President and CEO of PURE Bioscience, stated, "SDC is a perfect complement for DuraBan's product line, which features safe and green antimicrobial barrier technologies. DuraClean will be marketed through DuraBan's established distribution channels. These channels include a wide variety of markets, some of which will be significant new entry points for our SDC-based disinfectant, such as the industrial contracted services area."

DuraBan has registered DuraClean with the US EPA as a sub-registrant of PURE Bioscience and is currently undergoing registration in all 50 states. In accordance with the agreement, each bottle of DuraClean features PURE's "Powered by SDC" logo. The contract also provides for increasing annual minimum purchases; other specific terms of the contract were not disclosed.

DuraClean disinfectant carries a 30 second kill time on standard indicator bacteria, a 24 hour residual kill on standard indicator bacteria, a 2 minute kill time on some resistant strains of bacteria, 10 minute kill time on fungi, 30 second kill time on HIV Type I, and 10 minute kill time on other pathogenic viruses. These claims distinguish the efficacy of DuraClean from many of the leading commercial and consumer products currently on the market, while maintaining lower toxicity ratings. Based on the EPA toxicity ratings from Category I (high toxicity) down to Category IV, DuraClean is a Category IV antimicrobial for which precautionary labeling statements are not required. This compares with Category II warning statements for most leading brands of disinfectant products.

About DuraBan

DuraBan International Inc, is a Minneapolis, Minn., based chemical manufacturer and emerging global innovator of built-in, earth-friendly, antimicrobial product protection. DuraBan engineers safe and durable antimicrobial solutions for consumer, industrial and medical products around the world. Its technology can be engineered into a variety of surfaces and materials including: coatings, polymers, textiles, lumber, plastic and adhesives. Built-in to products during the manufacturing process, DuraBan antimicrobial product protection inhibits the growth of microbes, such as bacteria, mold and mildew that can cause stains, odors and product deterioration. DuraBan's proprietary and patented antimicrobial technologies deliver unmatched performance, durability and efficacy through a unique formulation based on surface-modifying nanotechnology. Once applied, DuraBan chemically bonds to the product surface, creating a permanent antimicrobial barrier that destroys microorganisms upon contact. DuraBan's antimicrobial has never been shown to allow or cause microbial adaptation, resistance, mutation, diffusion, or migration and easily bonds to almost any surface, creating unlimited applications for this breakthrough technology. For more information, please visit

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

PURE Bioscience Investor Contact:

Paul G. Henning, Vice President

Cameron Associates

(212) 554-5462

SOURCE PURE Bioscience
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
6. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc.
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 Studies ... and human plaque and pave the way for more effective ... in cats     --> ... commonly diagnosed health problems in cats, yet relatively little was ... Two collaborative studies have been conducted by researchers from the ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership ... Professionals (OPBAP) has been formalized with the signing of a Memorandum of Understanding. ... OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, ...
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
Breaking Biology Technology:
(Date:11/17/2015)... 17, 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ... and sale of broadly enabling, pressure cycling technology ("PCT")-based ... today announced it has received gross proceeds of $745,000 ... Placement (the "Offering"), increasing the total amount raised to ... additional closings are expected in the near future. ...
(Date:11/11/2015)...   MedNet Solutions , an innovative SaaS-based eClinical technology ... pleased to announce that it will be a Sponsor of ... to be held November 17-19 in Hamburg ... of iMedNet , MedNet,s easy-to-use, proven and ... has been able to deliver time and cost savings of ...
(Date:11/4/2015)... , November 4, 2015 ... market report published by Transparency Market Research "Home Security Solutions ... and Forecast 2015 - 2022", the global home security solutions ... bn by 2022. The market is estimated to expand ... from 2015 to 2022. Rising security needs among customers ...
Breaking Biology News(10 mins):